A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Gut Barrier and Inflammation: Deliver to the Site, Not the Blood

For the gut, poor systemic absorption can be an advantage: an active that stays in the lumen and releases at the right segment acts where the barrier is. Colon-targeted drug products already use pH-dependent and multi-matrix coatings. Vegalab applies the same logic to lawful ingredients and to research programs with partners.

The barrier and how it fails

A single layer of epithelial cells, sealed by tight junctions and covered by mucus, separates gut contents from the immune system. Increased permeability is measurable (for example by lactulose and mannitol urinary ratios) and is seen in inflammatory bowel disease and celiac disease. Whether it drives symptoms in the general population is not established; the term leaky gut outruns the evidence. Inflammatory signaling (TNF-alpha, IL-1 beta) both results from and worsens barrier loss.

Actives and their evidence

Budesonide in a multi-matrix colon-release tablet is FDA approved for ulcerative colitis, showing that site-targeted release works. Curcumin and berberine are supplement ingredients with very low oral bioavailability; much of their action, if any, is local or via gut microbes. KPV, the C-terminal tripeptide of alpha-MSH, reduced colitis in mice when delivered in nanoparticles inside a hydrogel; it is an unapproved research compound. BPC-157 is discussed on its own page and is limited to animal data.

Designing for location

Gastric pH is 1 to 3, rising to about 7 in the terminal ileum, and transit to the colon takes several hours. Enteric polymers that dissolve above pH 6 or 7, enzyme-triggered coatings and mucoadhesive layers let a formulator choose where release begins. The challenge pages on gastric degradation and protease degradation cover how peptides survive the journey. Location is verified in vitro first, then with imaging or sampling studies where a partner program justifies it.

Key facts

Increased intestinal permeability is documented in inflammatory bowel disease, but its role in other conditions remains unproven (Camilleri 2019, Gut 68:1516)
Budesonide extended-release tablets using multi-matrix colonic release are FDA approved for active mild to moderate ulcerative colitis (FDA label, Uceris 2013)
Nanoparticle-encapsulated KPV in a hydrogel reduced colitis severity in mice (Laroui et al. 2010, Gastroenterology 138:843)
Curcumin has poor oral bioavailability due to low absorption, rapid metabolism and elimination (Anand et al. 2007, Mol Pharm 4:807)

How our delivery technology applies

Multi-layer encapsulation lets release location be set by design. An outer layer resistant to gastric acid, a middle layer that erodes at intestinal pH, and a mucoadhesive inner layer can deliver a payload to the distal gut and hold it against the mucosa. For peptides like KPV this also limits protease exposure en route. Release location is verified in staged dissolution tests across pH 1.2, 6.8 and 7.4 media.

Design a site-targeted gut formulation with Vegalab's development team.